## Peter Brust

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/265745/publications.pdf

Version: 2024-02-01

		218381	377514
116	1,868	26	34
papers	citations	h-index	g-index
119	119	119	1606
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Discovery and development of brain-penetrant 18F-labeled radioligands for neuroimaging of the sigma-2 receptors. Acta Pharmaceutica Sinica B, 2022, 12, 1406-1415.	5.7	6
2	Non-Invasive Assessment of Locally Overexpressed Human Adenosine 2A Receptors in the Heart of Transgenic Mice. International Journal of Molecular Sciences, 2022, 23, 1025.	1.8	1
3	Amphiphilic Anionic Oligomer-Stabilized Calcium Phosphate Nanoparticles with Prospects in siRNA Delivery via Convection-Enhanced Delivery. Pharmaceutics, 2022, 14, 326.	2.0	6
4	Synthesis and characterization of the two enantiomers of a chiral sigma-1 receptor radioligand: (S)-(+)- and (R)-(-)-[18F]FBFP. Chinese Chemical Letters, 2022, 33, 3543-3548.	4.8	6
5	Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain. Pharmaceuticals, 2022, 15, 324.	1.7	0
6	Automated radiosynthesis of the adenosine A <sub>2A</sub> receptorâ€targeting radiotracer [ <sup>18</sup> F]FLUDA. Journal of Labelled Compounds and Radiopharmaceuticals, 2022, , .	0.5	1
7	Quantitation of the A2A Adenosine Receptor Density in the Striatum of Mice and Pigs with [18F]FLUDA by Positron Emission Tomography. Pharmaceuticals, 2022, 15, 516.	1.7	3
8	Structure-Based Design, Optimization, and Development of [ <sup>18</sup> F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET. Journal of Medicinal Chemistry, 2022, 65, 9034-9049.	2.9	10
9	(+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer's disease and healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 731-746.	3.3	10
10	Synthesis and Biological Evaluation of a Novel 18F-Labeled Radiotracer for PET Imaging of the Adenosine A2A Receptor. International Journal of Molecular Sciences, 2021, 22, 1182.	1.8	10
11	Development of 18F-Labeled Radiotracers for PET Imaging of the Adenosine A2A Receptor: Synthesis, Radiolabeling and Preliminary Biological Evaluation. International Journal of Molecular Sciences, 2021, 22, 2285.	1.8	5
12	Preclinical Evaluation of [18F]FACH in Healthy Mice and Piglets: An 18F-Labeled Ligand for Imaging of Monocarboxylate Transporters with PET. International Journal of Molecular Sciences, 2021, 22, 1645.	1.8	0
13	Improved in vivo PET imaging of the adenosine A2A receptor in the brain using [18F]FLUDA, a deuterated radiotracer with high metabolic stability. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2727-2736.	3.3	18
14	Validation of an LC-MS/MS Method to Quantify the New TRPC6 Inhibitor SH045 (Larixyl) Tj ETQq0 0 0 rgBT /Over Pharmaceuticals, 2021, 14, 259.	rlock 10 Tf 1.7	f 50 227 Td (N 3
15	Pathophysiological Changes in the Enteric Nervous System of Rotenone-Exposed Mice as Early Radiological Markers for Parkinson's Disease. Frontiers in Neurology, 2021, 12, 642604.	1.1	8
16	Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016. International Journal of Molecular Sciences, 2021, 22, 3832.	1.8	4
17	Synthesis of Novel Fluorinated Xanthine Derivatives with High Adenosine A2B Receptor Binding Affinity. Pharmaceuticals, 2021, 14, 485.	1.7	1
18	Design, Radiosynthesis and Preliminary Biological Evaluation in Mice of a Brain-Penetrant 18F-Labelled Ïf 2 Receptor Ligand. International Journal of Molecular Sciences, 2021, 22, 5447.	1.8	6

#	Article	IF	CITATIONS
19	Development of [18F]LU14 for PET Imaging of Cannabinoid Receptor Type 2 in the Brain. International Journal of Molecular Sciences, 2021, 22, 8051.	1.8	8
20	In vitro and in vivo evaluation of fluorinated indanone derivatives as potential positron emission tomography agents for the imaging of monoamine oxidase B in the brain. Bioorganic and Medicinal Chemistry Letters, 2021, 48, 128254.	1.0	7
21	Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1103-1115.	3.3	28
22	PET Imaging of the α4β2* Nicotinic Acetylcholine Receptors in Alzheimer's Disease. , 2021, , 345-365.		0
23	In Silico Finding of Key Interaction Mediated $\hat{l}\pm3\hat{l}^24$ and $\hat{l}\pm7$ Nicotinic Acetylcholine Receptor Ligand Selectivity of Quinuclidine-Triazole Chemotype. International Journal of Molecular Sciences, 2020, 21, 6189.	1.8	5
24	Newly Synthesized Fluorinated Cinnamylpiperazines Possessing Low In Vitro MAO-B Binding. Molecules, 2020, 25, 4941.	1.7	4
25	Development of Novel Analogs of the Monocarboxylate Transporter Ligand FACH and Biological Validation of One Potential Radiotracer for Positron Emission Tomography (PET) Imaging. Molecules, 2020, 25, 2309.	1.7	4
26	Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(â^')-[18F]Fluspidine in Glioblastoma. Molecules, 2020, 25, 2170.	1.7	5
27	Preclinical Incorporation Dosimetry of [18F]FACH—A Novel 18F-Labeled MCT1/MCT4 Lactate Transporter Inhibitor for Imaging Cancer Metabolism with PET. Molecules, 2020, 25, 2024.	1.7	3
28	The sigma-1 receptor: Potential role in the modulation of cellular radiation sensitivity. Journal of Cellular Biotechnology, 2020, , 1-9.	0.1	0
29	Development of a Radiofluorinated Adenosine A2B Receptor Antagonist as Potential Ligand for PET Imaging. International Journal of Molecular Sciences, 2020, 21, 3197.	1.8	3
30	Positron Emission Tomography Imaging Evaluation of a Novel 18F-Labeled Sigma-1 Receptor Radioligand in Cynomolgus Monkeys. ACS Chemical Neuroscience, 2020, 11, 1673-1681.	1.7	10
31	PET Imaging of the Adenosine A2A Receptor in the Rotenone-Based Mouse Model of Parkinson's Disease with [18F]FESCH Synthesized by a Simplified Two-Step One-Pot Radiolabeling Strategy. Molecules, 2020, 25, 1633.	1.7	12
32	Synthesis and evaluation of new 1-oxa-8-azaspiro [4.5] decane derivatives as candidate radioligands for sigma-1 receptors. Bioorganic and Medicinal Chemistry, 2020, 28, 115560.	1.4	6
33	Imaging sigma receptors in the brain: New opportunities for diagnosis of Alzheimer's disease and therapeutic development. Neuroscience Letters, 2019, 691, 3-10.	1.0	24
34	In vitro and in vivo Human Metabolism of (S)-[18F]Fluspidine – A Radioligand for Imaging σ1 Receptors With Positron Emission Tomography (PET). Frontiers in Pharmacology, 2019, 10, 534.	1.6	9
35	Synthesis and In Vitro Evaluation of 8-Pyridinyl-Substituted Benzo[e]imidazo[2,1-c][1,2,4]triazines as Phosphodiesterase 2A Inhibitors. Molecules, 2019, 24, 2791.	1.7	9
36	Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18. Bioorganic Chemistry, 2019, 86, 346-362.	2.0	14

#	Article	IF	CITATIONS
37	Structureâ€"Affinity Relationships of Fluorinated Spirocyclic σ 2 Receptor Ligands with an Exocyclic Benzylamino Moiety. ChemMedChem, 2019, 14, 1392-1402.	1.6	1
38	Development and radiosynthesis of the first <sup>18</sup> Fâ€labeled inhibitor of monocarboxylate transporters (MCTs). Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 411-424.	0.5	6
39		0.5	2
40	Application of Fourier Analysis of Cerebral Glucose Metabolism in Color-Induced Long-Term Potentiation: A Novel Functional PET Spectroscopy (fPETS) Study in Mice., 2019,,.		0
41	One-step radiosynthesis of the MCTs imaging agent [18F]FACH by aliphatic 18F-labelling of a methylsulfonate precursor containing an unprotected carboxylic acid group. Scientific Reports, 2019, 9, 18890.	1.6	5
42	Radiosynthesis and Biological Investigation of a Novel Fluorine-18 Labeled Benzoimidazotriazine-Based Radioligand for the Imaging of Phosphodiesterase 2A with Positron Emission Tomography. Molecules, 2019, 24, 4149.	1.7	5
43	Studies towards the development of a PET radiotracer for imaging of the P2Y1 receptors in the brain: synthesis, 18F-labeling and preliminary biological evaluation. European Journal of Medicinal Chemistry, 2019, 165, 142-159.	2.6	12
44	Synthesis and radiofluorination of novel fluoren-9-one based derivatives for the imaging of $\hat{l}\pm7$ nicotinic acetylcholine receptor with PET. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1471-1475.	1.0	7
45	Fourier Analysis of Cerebral Metabolism of Glucose: Gender Differences in Mechanisms of Color Processing in the Ventral and Dorsal Streams in Mice. Forecasting, 2018, 1, 135-156.	1.6	1
46	Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic $\ddot{l}f$ Receptor Ligands with Exocyclic Amino Moiety. Journal of Medicinal Chemistry, 2018, 61, 9666-9690.	2.9	9
47	Investigation of an 18F-labelled Imidazopyridotriazine for Molecular Imaging of Cyclic Nucleotide Phosphodiesterase 2A. Molecules, 2018, 23, 556.	1.7	9
48	Bridging from Brain to Tumor Imaging: (S)-( $\hat{a}$ ')- and (R)-(+)-[18F]Fluspidine for Investigation of Sigma-1 Receptors in Tumor-Bearing Mice. Molecules, 2018, 23, 702.	1.7	9
49	Radiosynthesis and in vivo evaluation of a fluorine-18 labeled pyrazine based radioligand for PET imaging of the adenosine A2B receptor. Bioorganic and Medicinal Chemistry, 2018, 26, 4650-4663.	1.4	17
50	Exploring the Metabolism of (+)-[18F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided Identification of Radiometabolites in a Clinical PET Study â€. Molecules, 2018, 23, 464.	1.7	9
51	Radiosynthesis and biological evaluation of the new PDE10A radioligand [ <sup>18</sup> F]AQ28A. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 36-48.	0.5	15
52	PET Imaging Evaluation of Four $ f $ sub>1 Radiotracers in Nonhuman Primates. Journal of Nuclear Medicine, 2017, 58, 982-988.	2.8	24
53	PET imaging of $\hat{l}\pm7$ nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1042-1050.	3.3	47
54	1-(4-[ $<$ sup $>$ 18 $<$ /sup $>$ F]Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: A Novel Suitable Radioligand with Low Lipophilicity for Imaging If $<$ sub $>$ 1 $<$ /sub $>$ Receptors in the Brain. Journal of Medicinal Chemistry, 2017, 60, 4161-4172.	2.9	24

#	Article	IF	CITATIONS
55	Synthesis and inÂvitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes. European Journal of Medicinal Chemistry, 2017, 136, 548-560.	2.6	18
56	Development of Highly Affine and Selective Fluorinated Cannabinoid Type 2 Receptor Ligands. ACS Medicinal Chemistry Letters, 2017, 8, 566-571.	1.3	10
57	18 F-Labeled indole-based analogs as highly selective radioligands for imaging sigma-2 receptors in the brain. Bioorganic and Medicinal Chemistry, 2017, 25, 3792-3802.	1.4	18
58	The evaluations of 99m Tc cyclopentadienyl tricarbonyl triphenyl phosphonium cation for multidrug resistance. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3551-3554.	1.0	7
59	PET Imaging for Early Detection of Alzheimer's Disease. PET Clinics, 2017, 12, 329-350.	1.5	44
60	Radiosynthesis of (S)-[18 F] T1: The first PET radioligand for molecular imaging of $\hat{l}\pm3\hat{l}^24$ nicotinic acetylcholine receptors. Applied Radiation and Isotopes, 2017, 124, 106-113.	0.7	6
61	Do spiroindolines have the potential to replace vesamicol as lead compound for the development of radioligands targeting the vesicular acetylcholine transporter?. Bioorganic and Medicinal Chemistry, 2017, 25, 5107-5113.	1.4	9
62	Synthesis and Preliminary Biological Evaluation of Indol-3-yl-oxoacetamides as Potent Cannabinoid Receptor Type 2 Ligands. Molecules, 2017, 22, 77.	1.7	3
63	Development of Fluorinated Non-Peptidic Ghrelin Receptor Ligands for Potential Use in Molecular Imaging. International Journal of Molecular Sciences, 2017, 18, 768.	1.8	10
64	Gender differences in cerebral metabolism for color processing in mice: A PET/MRI Study. PLoS ONE, 2017, 12, e0179919.	1.1	4
65	Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012. Molecules, 2016, 21, 650.	1.7	21
66	Evaluation of the Enantiomer Specific Biokinetics and Radiation Doses of [18F]Fluspidine $\hat{a} \in \text{``A New}$ Tracer in Clinical Translation for Imaging of $\hat{l}f1$ Receptors. Molecules, 2016, 21, 1164.	1.7	34
67	LC-MS Supported Studies on the in Vitro Metabolism of both Enantiomers of Flubatine and the in Vivo Metabolism of (+)-[18F]Flubatine—A Positron Emission Tomography Radioligand for Imaging α4β2 Nicotinic Acetylcholine Receptors. Molecules, 2016, 21, 1200.	1.7	12
68	Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain. Pharmaceuticals, 2016, 9, 22.	1.7	15
69	A novel thermoregulatory role for <scp>PDE</scp> 10A in mouse and human adipocytes. EMBO Molecular Medicine, 2016, 8, 796-812.	3.3	34
70	Comparison of inâ $\in$ Silico, Electrochemical, inâ $\in$ Vitro and inâ $\in$ Vivo Metabolism of a Homologous Series of (Radio)fluorinated $\ddot{i}f$ <sub>1</sub> Receptor Ligands Designed for Positron Emission Tomography. ChemMedChem, 2016, 11, 2445-2458.	1.6	12
71	Varying Chirality Across Nicotinic Acetylcholine Receptor Subtypes: Selective Binding of Quinuclidine Triazole Compounds. ACS Medicinal Chemistry Letters, 2016, 7, 890-895.	1.3	10
72	Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor. Journal of Medicinal Chemistry, 2016, 59, 7840-7855.	2.9	47

#	Article	IF	Citations
73	Radiation dosimetry of the $\hat{l}\pm4\hat{l}^22$ nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results. EJNMMI Physics, 2016, 3, 25.	1.3	17
74	Development of a Novel Nonpeptidic <sup>18</sup> F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 1800-1817.	2.9	17
75	Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and inÂvitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines. European Journal of Medicinal Chemistry, 2016, 107, 97-108.	2.6	13
76	PET imaging evaluation of [18F]DBT-10, a novel radioligand specific to $\hat{l}\pm7$ nicotinic acetylcholine receptors, in nonhuman primates. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 537-547.	3.3	20
77	Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography. Molecules, 2015, 20, 9591-9615.	1.7	17
78	A Promising PET Tracer for Imaging of $\hat{l}\pm7$ Nicotinic Acetylcholine Receptors in the Brain: Design, Synthesis, and in Vivo Evaluation of a Dibenzothiophene-Based Radioligand. Molecules, 2015, 20, 18387-18421.	1.7	13
79	sup>18, $up>F$ -Labeled 1,4-Dioxa-8-azaspiro [4.5] decane Derivative: Synthesis and Biological Evaluation of a $uprox 1$ , $uprox 1$ , $uprox 2$ , $uprox 2$ , $uprox 3$ , $uprox 3$ , $uprox 4$ , $uprox 2$ , $uprox 3$ , $uprox 4$ , $uprox 2$ , $uprox 3$ , $uprox 3$ , $uprox 3$ , $uprox 4$ , $uprox 3$ , $uprox 4$	2.9	26
80	Convenient recycling and reuse of bombarded [ $18O$ ]H $2O$ for the production and the application of [ $18F$ ]F $\hat{a}^{2}$ . Applied Radiation and Isotopes, 2015, 101, 44-52.	0.7	9
81	First-in-human PET quantification study of cerebral $\hat{l}\pm4\hat{l}^22^*$ nicotinic acetylcholine receptors using the novel specific radioligand ( $\hat{a}$ ')-[18F]Flubatine. Neurolmage, 2015, 118, 199-208.	2.1	49
82	A high-yield automated radiosynthesis of the alpha-7 nicotinic receptor radioligand [18F]NS10743. Applied Radiation and Isotopes, 2015, 95, 76-84.	0.7	10
83	Novel 18F-labeled dibenzylideneacetone derivatives as potential positron emission tomography probes for inÂvivo imaging of $\hat{l}^2$ -amyloid plaques. European Journal of Medicinal Chemistry, 2014, 84, 628-638.	2.6	9
84	Internal Dose Assessment of (–)- <sup>18</sup> F-Flubatine, Comparing Animal Model Datasets of Mice and Piglets with First-in-Human Results. Journal of Nuclear Medicine, 2014, 55, 1885-1892.	2.8	17
85	Fluorineâ€Containing 6,7â€Dialkoxybiarylâ€Based Inhibitors for Phosphodiesteraseâ€10 A: Synthesis and ir vitro Evaluation of Inhibitory Potency, Selectivity, and Metabolism. ChemMedChem, 2014, 9, 1476-1487.	1.6	13
86	Distinctive In Vivo Kinetics of the New $ f $ sub>1 Receptor Ligands ( <i>R</i> )-(+)- and ( <i>S</i> )-( $a\in$ ")- <sup>18</sup> F-Fluspidine in Porcine Brain. Journal of Nuclear Medicine, 2014, 55, 1730-1736.	2.8	26
87	Development of 18F-labeled radiotracers for neuroreceptor imaging with positron emission tomography. Neuroscience Bulletin, 2014, 30, 777-811.	1.5	46
88	Carbon-11 labeled stilbene derivatives from natural products for the imaging of A <i><math>\hat{l}^2</math></i> plaques in the brain. Radiochimica Acta, 2014, 102, 185-192.	0.5	0
89	Automation of the radiosynthesis and purification procedures for [18F]Fluspidine preparation, a new radiotracer for clinical investigations in PET imaging of $\ddot{l}f1$ receptors in brain. Applied Radiation and Isotopes, 2014, 84, 1-7.	0.7	17
90	Synthesis and biological evaluation of both enantiomers of [18F]flubatine, promising radiotracers with fast kinetics for the imaging of $\hat{l}\pm4\hat{l}^2$ 2-nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 2014, 22, 804-812.	1.4	29

#	Article	IF	CITATIONS
91	$^{\circ}$	3.5	28
92	Synthesis and evaluation of a 18F-labeled spirocyclic piperidine derivative as promising $\dagger f1$ receptor imaging agent. Bioorganic and Medicinal Chemistry, 2014, 22, 5270-5278.	1.4	17
93	Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (â^')-[18F]Flubatine in humans. Nuclear Medicine and Biology, 2014, 41, 489-494.	0.3	18
94	Radiosynthesis of racemic and enantiomerically pure (â°')-[18F]flubatineâ€"A promising PET radiotracer for neuroimaging of α4β2 nicotinic acetylcholine receptors. Applied Radiation and Isotopes, 2013, 74, 128-136.	0.7	25
95	A fluoro versus a nitro derivativeâ€"a high-performance liquid chromatography study of two basic analytes with different reversed phases and silica phases as basis for the separation of a positron emission tomography radiotracer. Journal of Chromatography A, 2013, 1311, 98-105.	1.8	5
96	Radiofluorination and biological evaluation of N-aryl-oxadiazolyl-propionamides as potential radioligands for PET imaging of cannabinoid CB2 receptors. Organic and Medicinal Chemistry Letters, 2013, 3, 11.	2.0	22
97	Synthesis, Characterization, and Metabolism Studies of Fluspidine Enantiomers. ChemMedChem, 2013, 8, 2047-2056.	1.6	29
98	Radiosynthesis and first evaluation in mice of [18F]NS14490 for molecular imaging of $\hat{l}\pm7$ nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 2013, 21, 2635-2642.	1.4	31
99	Fully automated radiosynthesis of both enantiomers of [18F]Flubatine under GMP conditions for human application. Applied Radiation and Isotopes, 2013, 80, 7-11.	0.7	20
100	Radiosynthesis and Radiotracer Properties of a 7-(2-[18F]Fluoroethoxy)-6-methoxypyrrolidinylquinazoline for Imaging of Phosphodiesterase 10A with PET. Pharmaceuticals, 2012, 5, 169-188.	1.7	16
101	Synthesis and Evaluation of Novel $\langle \sup 18 \rangle$ sup F Labeled 2-Pyridinylbenzoxazole and 2-Pyridinylbenzothiazole Derivatives as Ligands for Positron Emission Tomography (PET) Imaging of $\hat{l}^2$ -Amyloid Plaques. Journal of Medicinal Chemistry, 2012, 55, 9283-9296.	2.9	45
102	Cannabinoid receptor type 2 (CB2)-selective N-aryl-oxadiazolyl-propionamides: synthesis, radiolabelling, molecular modelling and biological evaluation. Organic and Medicinal Chemistry Letters, 2012, 2, 32.	2.0	32
103	Development of Radioligands for the Imaging of ?7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography. Current Drug Targets, 2012, 13, 594-601.	1.0	26
104	Molecular imaging of $\dagger f$ receptors: synthesis and evaluation of the potent $\dagger f$ 1 selective radioligand [18F]fluspidine. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 540-551.	3.3	66
105	Assessment of $\hat{l}\pm 7$ nicotinic acetylcholine receptor availability in juvenile pig brain with [18F]NS10743. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1541-1549.	3.3	34
106	Synthesis, pharmacological activity and structure affinity relationships of spirocyclic $\ddot{l}f1$ receptor ligands with a (2-fluoroethyl) residue in 3-position. Bioorganic and Medicinal Chemistry, 2011, 19, 393-405.	1.4	46
107	Synthesis and biodistribution of novel <sup>99m</sup> Tcâ€nitrido methylpiperidine dithioformate derivatives as potential brain imaging agents. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 183-188.	0.5	5
108	Molecular imaging of $\hat{l}\pm7$ nicotinic acetylcholine receptors: design and evaluation of the potent radioligand [18F]NS10743. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 791-800.	3.3	36

#	Article	IF	CITATIONS
109	Synthesis of spirocyclic σ1 receptor ligands as potential PET radiotracers, structure–affinity relationships and in vitro metabolic stability. Bioorganic and Medicinal Chemistry, 2009, 17, 3630-3641.	1.4	36
110	Evaluation of Spirocyclic 3-(3-Fluoropropyl)-2-benzofurans as $\ddot{l}f$ (sub) Receptor Ligands for Neuroimaging with Positron Emission Tomography. Journal of Medicinal Chemistry, 2009, 52, 6062-6072.	2.9	49
111	In vivo measurement of nicotinic acetylcholine receptors with [ <sup>18</sup> F]norchloroâ€fluoroâ€homoepibatidine. Synapse, 2008, 62, 205-218.	0.6	47
112	A new 18F-labeled fluoroacetylmorpholino derivative of vesamicol for neuroimaging of the vesicular acetylcholine transporter. Nuclear Medicine and Biology, 2008, 35, 185-195.	0.3	34
113	Novel 99mTc labeled $\ddot{l}f$ receptor ligand as a potential tumor imaging agent. Science in China Series B: Chemistry, 2006, 49, 169-176.	0.8	20
114	Norchloro-fluoro-homoepibatidine: specificity to neuronal nicotinic acetylcholine receptor subtypes in vitro. Il Farmaco, 2004, 59, 785-792.	0.9	35
115	Positron emission tomography imaging of the serotonin transporter in the pig brain using [11C](+)-McN5652 and S-([18F]fluoromethyl)-(+)-McN5652. Synapse, 2003, 47, 143-151.	0.6	32
116	Solvation effects on brain uptakes of isomers of 99m Tc brain imaging agents. Science Bulletin, 2002, 47, 1786-1791.	4.3	0